HemaSphere (Jun 2022)

P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL

  • P. L. Zinzani,
  • S. M. Ansell,
  • F. Bosch,
  • J. W. Friedberg,
  • J. P. Marolleau,
  • L. Arcaini,
  • R. Garcia-Sanz,
  • A. K. Gopal,
  • C. Grande,
  • R. Merryman,
  • A. Pinto,
  • S. D. Smith,
  • J. C. Villasboas,
  • D. Wallace,
  • J. Fagerberg,
  • J. G. Magalhaes,
  • P. Armand

DOI
https://doi.org/10.1097/01.HS9.0000847328.48663.29
Journal volume & issue
Vol. 6
pp. 1005 – 1006

Abstract

Read online

No abstracts available.